Waxmonsky JG, Pelham W 3rd, Campa A, Waschbusch DA, Li T, Marshall R, Babocsai L, Humphery H, Gnagy E, Swanson J, Hanc T, Fallahazad N, Pelham WE 4th. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry 2019:29 de agosto. [Ref.ID 103191]

Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues A, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow C-M, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology 2019:6 de marzo. [Ref.ID 103052]

Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open 2018;8:. [Ref.ID 102510]

Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424-34. [Ref.ID 100458]

Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, Andreasen AH, Jensen CB, DeFronzo RA, for the NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. The SCALE diabetes randomized clinical trial. JAMA 2015;314:687-99. [Ref.ID 99409]

Anónimo. Liraglutide (Saxenda) for weight loss. Med Lett Drugs Ther 2015;57:7-8. [Ref.ID 99215]

Schumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukaris AG, Kiyota N, Taylor MH, Kim S-B, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radiodiodine-refractory thyroid cancer. N Engl J Med 2015;372:621-30. [Ref.ID 98795]

Anónimo. Thyroid cancer treatment performs well in clinical trial, FDA approval expected. DIA Daily 2014:13 de febrero. [Ref.ID 98776]

Astrup A, Madsbad S, Breum L, Jensen TJ. Under-reporting of adverse effects of tesofensine. Lancet 2013;382:127. [Ref.ID 95827]

Franco M, Bilal U, Orduñez P, Benet M, Morejón A, Caballero B, Kennelly JF, Cooper RS. Population-wide weight loss and regain in relation to diabetes burden and cardiovascular mortality in Cuba 1980-2010: repeated cross sectional surveys and ecological comparison of secular trends. BMJ 2013;346:15. [Ref.ID 95442]

van der Graaf W, Judson I, Dei Tos AP, Litiere S, Blay J-Y. Pazopanib for metastatic soft-tissue sarcoma. Authors' reply. Lancet 2012;380:801-2. [Ref.ID 93715]

Endo M, Nielsen TO. Pazopanib for metastatic soft-tissue sarcoma. Lancet 2012;380:801. [Ref.ID 93714]

Anónimo. FDA approves Cometriq to treat rare type of thyroid cancer. U.S. Food and Drug Administration 2012:29 de noviembre. [Ref.ID 93268]

Anónimo. FDA clears advanced-colorectal cancer treatment. DIA Daily 2012:28 de septiembre. [Ref.ID 93061]

van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P, on behalf of the EORTC Soft Tissue and Bone Sarcoma Group and the PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86. [Ref.ID 93018]

Bramwell VHC. Pazopanib and the treatment palette for soft-tissue sarcoma. Lancet 2012;379:1854-6. [Ref.ID 93011]

Karagiannis T, Paschos P, Paletas K, Matthews DR. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369. [Ref.ID 92518]

Vilsboll T, Christensen M, Junker AE, Knopf FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.. BMJ 2012;344:14. [Ref.ID 92292]

Padwal R. Glucagon-like peptide-1 agonists. BMJ 2012;344:7. [Ref.ID 92290]

Anónimo. Vildagliptin – a new oral antidiabetic agent. Signal 2011:13-4. [Ref.ID 91692]